Moderate

Polycythaemia vera (PV; primary polycythaemia, JAK2-positive erythrocytosis)

Myeloproliferative neoplasm · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

JAK2 V617F-driven clonal overproduction of red cells (+/- platelets, neutrophils). Raised haematocrit increases hyperviscosity and thrombosis risk (arterial + venous, including splanchnic). ED priorities: recognise, exclude/treat thrombosis, urgent venesection if symptomatic hyperviscosity, start aspirin, refer haematology.

Red flags

  • Acute arterial/venous thrombosis, including splanchnic (abdominal pain + ascites = Budd-Chiari)
  • Hyperviscosity: visual disturbance, headache, dizziness, confusion, chest pain
  • Transient ischaemic attack / stroke
  • Erythromelalgia (burning red hands/feet) with very high platelets
  • Massive splenomegaly / transformation symptoms (weight loss, fever)

Assessment

Differential diagnosis

  • Secondary erythrocytosis (hypoxia/COPD/OSA/high altitude, smoking, EPO-secreting tumour)
  • Relative/apparent polycythaemia (dehydration, Gaisbock)
  • Essential thrombocythaemia / other MPN
  • Congenital high-affinity haemoglobinopathy
  • Androgen/testosterone use

Investigations

  • FBC: raised Hb/haematocrit (+/- raised platelets, WCC); confirm true red cell mass picture
  • JAK2 V617F mutation (positive in ~95%); JAK2 exon 12 if negative and PV suspected
  • Serum erythropoietin (low in PV, high in secondary)
  • Ferritin (often low), U&E, urate, LDH
  • USS abdomen for splenomegaly; SpO2/ABG to exclude hypoxic cause
  • Bone marrow + BCR-ABL only if diagnostic doubt per haematology

Management

  • Assess for acute thrombosis (stroke, MI, DVT/PE, Budd-Chiari/portal vein) and treat per that pathway
  • If symptomatic hyperviscosity (visual change, headache, confusion, thrombosis): urgent venesection to lower haematocrit
  • Target haematocrit <0.45 in all PV patients (reduces thrombotic events)
  • Start low-dose aspirin unless contraindicated
  • Control cardiovascular risk factors; hydrate
  • Start cytoreduction (hydroxycarbamide) in high-risk patients (age >60 or prior thrombosis) - haematology-directed
  • Manage aquagenic pruritus; allopurinol if hyperuricaemia
  • Avoid unnecessary blood transfusion; correct the thrombotic, not just the count

Drugs & doses

Venesection - remove ~450 mL (less if elderly/cardiac) to target Hct <0.45, repeat per response [verify local dose]
Aspirin 75-100 mg PO once daily (unless bleeding/contraindication)
Hydroxycarbamide (hydroxyurea) 15-20 mg/kg/day PO, titrate to counts (first-line cytoreduction, high-risk) [verify local dose]
Ruxolitinib (JAK inhibitor) for hydroxycarbamide-resistant/intolerant disease [verify local dose]
Interferon alfa / peginterferon as cytoreduction esp. younger patients/pregnancy [verify local dose]
Allopurinol 100-300 mg PO once daily if hyperuricaemia [verify local dose]

Disposition

Acute thrombosis/hyperviscosity -> admit, treat, urgent haematology. Otherwise outpatient haematology referral for confirmation and risk-stratified cytoreduction.

Complications & pitfalls

  • Arterial and venous thrombosis (leading cause of death)
  • Haemorrhage (acquired von Willebrand with very high platelets)
  • Transformation to myelofibrosis or acute myeloid leukaemia
  • Gout, pruritus, peptic ulceration

Exam pearls

  • Keep haematocrit <0.45 - the CYTO-PV trial showed fewer cardiovascular deaths/thromboses at this target
  • Low EPO + JAK2 positive = PV; high EPO points to secondary cause
  • New splanchnic vein thrombosis (Budd-Chiari/portal) in a young patient - test for JAK2 even if counts look normal
  • Paradoxical bleeding with extreme thrombocytosis = acquired von Willebrand syndrome - avoid aspirin until addressed
  • Avoid overtransfusion / iron supplements (fuels erythrocytosis)

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.